Functional imaging of the dopamine system: In vivo evaluation of dopamine deficiency and restoration

NeuroToxicology

Volumn 23, Issue 4-5, 2002, Pages 469-478

  Sanchez Pernautel R ^a   Brownell, A L ^a,b   Isacson, O ^a,b,c  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dopamine; Parkinson's disease; PET

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BENZAMIDE DERIVATIVE; CATECHOLAMINE; DOPA; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUORODOPA; LEVODOPA; METHYLPHENIDATE; NOMIFENSINE; PIMOZIDE; RACLOPRIDE; SPIPERONE; TETRABENAZINE; TRACER; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; BRAIN METABOLISM; BRAIN TOMOGRAPHY; CONFERENCE PAPER; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; HORMONE DEFICIENCY; HORMONE RECEPTOR INTERACTION; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; MICRODIALYSIS; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; IMAGE PROCESSING; METABOLISM; MOTONEURON; NERVE CELL NETWORK; NERVOUS SYSTEM; PATHOLOGY; PHYSIOLOGY; REVIEW; SYNAPTOSOME;

ANIMALIA;

ANIMALS; DOPAMINE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICRODIALYSIS; MOTOR NEURONS; NERVE NET; NERVOUS SYSTEM; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; RECEPTORS, DOPAMINE;

EID: 0036778187     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00064-5     Document Type: Conference Paper

References (84)

1. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-71.
2. Annett LE, Rogers DC, Hernandez TD, Dunnett SB. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 1992;115:825-56.
3. 11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-DOPA and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44:1325-9.
4. 11C]raclopride. Mov Disord 1997;12:33-8.
5. Barrio JR, Huang SC, Yu DC, Melega WP, Quintana J, Cherry SR, et al. Radiofluorinated L-m-tyrosines: new in-vivo probes for central dopamine biochemistry. J Cereb Blood Flow Metab 1996;16:667-78.
6. Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 2001;124:2131-46.
7. Bjorklund L, Pemaute RS, Chung S, Andersson T, Chen IYC, McNaught KSP, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002;99:2344-9.
8. Brooks DJ, Samuel M. The effects of surgical treatment of Parkinson's disease on brain function: PET findings. Neurology 2000;55:S52-9.
9. Brownell AL, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat Med 1998a;4:1308-12.
10. Brownell AL, Livni E, Galpern W, Isacson O. In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann Neurol 1998b;43:387-90.
11. Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000;123:1380-90.
12. Bums RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-50.
13. Catalan MJ, Ishii K, Honda M, Samii A, Hallett M. A PET study of sequential finger movements of varying length in patients with Parkinson's disease. Brain 1999;122(Pt 3):483-95.
14. Ceballos-Baumann AO, Boecker H, Bartenstein P, von Falkenhayn I, Riescher H, Conrad B, et al. A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch Neurol 1999;56:997-1003.
15. Cenci MA, Kalen P, Mandel RJ, Wictorin K, Bjorklund A. Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum. Neuroscience 1992;46:943-57.
16. 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 1999;40:283-9.
17. Dale AM, Halgren E. Spatiotemporal mapping of brain activity by integration of multiple imaging modalities. Curr Opin Neurobiol 2001;11:202-8.
18. Davis KD, Taub E, Houle S, Lang AE, Dostrovsky JO, Tasker RR, et al. Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nat Med 1997;3:671-4.
19. de la Fuente-Fernandez R, Pal PK, Vingerhoets FJ, Kishore A, Schulzer M, Mak EK, et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 2000;107:49-57.
20. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293:1164-6.
21. Deiber MP, Pollak P, Passingham R, Landais P, Gervason C, Cinotti L, et al. Thalamic stimulation and suppression of parkinsonian tremor. Evidence of a cerebellar deactivation using positron emission tomography. Brain 1993;116:267-79.
22. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-5.
23. 11C]raclopride PET study. Mov Disord 1999;14:1025-30.
24. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993a;13:350-6.
25. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, et al. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 1993b;90:11816-20.
26. 18F]fluoroepibatidine. J Neurochem 2000;74:1514-21.
27. Doudet DJ, Holden JE, Jivan S, McGeer E, Wyatt RJ. In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 2000;38:105-13.
28. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
29. Elsworth JD, Brittan MS, Taylor JR, Sladek Jr, JR, Redmond Jr, DE, Innis RB, et al. Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study. Brain Res 1998;795:55-62.
30. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-301.
31. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-9.
32. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-31.
33. Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain 2001;124:1601-9.
34. Gash DM, Zhang A, Umberger G, Mahood K, Smith M, Smith C, et al. An automated movement assessment panel for upper limb motor functions in rhesus monkeys and humans. J Neurosci Methods 1999;89:111-7.
35. Gerasimov MR, Ashby Jr, CR, Gardner EL, Mills MJ, Brodie JD, Dewey SL. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 1999;34:11-9.
36. Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 1999;122(Pt 6):1121-32.
37. 11C]-CFT and PET in a primate model of parkinsonism. NeuroReport 1992;3:265-8.
38. Haslinger B, Erhard P, Kampfe N, Boecker H, Rummeny E, Schwaiger M, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001;124:558-70.
39. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999;56:179-87.
40. Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001;49:367-76.
41. Hornykiewicz O. Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser 1975;3:13-21.
42. 11C-WIN 35,428. Ann Neurol 1994;35:377-8.
43. Isacson O, Bjorklund L, Pernaute RS. Parkinson's disease: interpretations of transplantation study are erroneous. Nat Neurosci 2001;4:553.
44. Jahanshahi M, Ardouin CM, Brown RG, Rothwell JC, Obeso J, Albanese A, et al. The impact of deep brain stimulation on executive function in Parkinson's disease. Brain 2000;123(Pt 6):1142-54.
45. Jenkins IH, Fernandez W, Playford ED, Lees AJ, Frackowiak RS, Passingham RE, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32:749-57.
46. 11C]N-methylspiperone. J Nucl Med 2000;41:65-70.
47. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, et al. Evidence for striatal dopamine release during a video game. Nature 1998;393:266-8.
48. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000;20:423-51.
49. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997a;17:162-74.
50. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997b;25:1-14.
51. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
52. Leenders KL, Aquilonius SM, Bergstrom K, Bjurling P, Crossman AR, Eckernas SA, et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res 1988;445:61-7.
53. Limousin P, Greene J, Pollak P, Rothwell J, Benabid AL, Frackowiak R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann Neurol 1997;42:283-91.
54. Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 1994;117(Pt 4):877-97.
55. 3H]L-DOPA in rats. Biochem Pharmacol 1990;39:1853-60.
56. 18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiat 1995;59:597-600.
57. 18F]6-fluoro-L-m-tyrosine in the human brain. Mov Disord 1995;10:298-304.
58. 18F]CFT. Ann Neurol 2000;47:804-8.
59. Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ann Neurol 1999;46:723-31.
60. Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, et al. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease. Brain 2001;124:784-92.
61. Parker F, Tzourio N, Blond S, Petit H, Mazoyer B. Evidence for a common network of brain structures involved in parkinsonian tremor and voluntary repetitive movement. Brain Res 1992;584:11-7.
62. Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-8.
63. Perlmutter JS, Kilbourn MR, Raichle ME, Welch MJ. MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology 1987;37:1575-9.
64. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient [see comments]. Nat Neurosci 1999;2:1137-40.
65. Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts [In Process Citation]. Ann Neurol 2000;48:689-95.
66. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122(Pt 8):1449-68.
67. Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol 1992;32:151-61.
68. Rascol O, Sabatini U, Fabre N, Brefel C, Loubinoux I, Celsis P, et al. The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients. Brain 1997;120(Pt 1):103-10.
69. Rinne JO, Laihinen A, Rinne UK, Nagren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993;8:134-8.
70. 11C]raclopride. J Neurol Sci 1995;132:156-61.
71. Sabatini U, Boulanouar K, Fabre N, Martin F, Carel C, Colonnese C, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000;123(Pt 2):394-403.
72. Samuel M, Ceballos-Baumann AO, Blin J, Uema T, Boecker H, Passingham RE, et al. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study. Brain 1997;120(Pt 6):963-76.
73. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RS. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naive parkinsonism. Diagnostic implications of the D2 receptor status. Brain 1993;116(Pt 4):853-67.
74. 11C]raclopride at dopamine receptors in human subjects. Am J Psychiat 1997;154:1209-13.
75. 11C-raclopride in normal human subjects. Neuropsychopharmacology 1998;18:18-25.
76. 11F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-30.
77. Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiat 2000;68:313-6.
78. 11C]raclopride displacement and PET. Neurology 1996;46:1430-6.
79. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-DOPA-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49:717-23.
80. Ungerstedt U, Arbuthnott G. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24:485-93.
81. Verhoeff NP. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology (Berl) 1999;147:217-49.
82. Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994;36:765-70.
83. Volkow ND, Wang GJ, Fowler JS, Logan J, Angrist B, Hitzemann R, et al. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am J Psychiat 1997;154:50-5.
84. Wenning G, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997;42:95-107.